Medicon Valley Alliance and IQVIA are pleased to invite you to a Good Morning Meeting on the 4th of October in Copenhagen focusing on how to create value for biotech companies through reducing risk, time to market and optimizing peak sales.
Early stage biotech companies need to fill the evidence gaps at their stage of pipeline development. Late-stage companies need to demonstrate a credible path to market. In general commercial insight is needed at all stages in the lifecycle if share prices and funding should reach its full potential.
At this MVA morning meeting IQVIA’s expert Christopher Ball will take you through the stages of biotech development focusing on the challenges and opportunities for biotech to reach their full value potential.
Date: Wednesday, 4th of October, 2023
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 13, 2300 Copenhagen S, Denmark – Meeting room: Lab
Program
| 08:30 | Networking, registration, and light breakfast |
| 09:00 | Welcome David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 09:05 | Company Introduction IQVIA Ditlev Moltke, Commercial Director, Nordics |
| 09:15 | How to create value for biotech companies – through reducing risk, time to market and optimizing peak sales Dr. Christopher Ball, Asset Partner, IQVIA |
| 10:00 | Q&A session |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
| Speaker | |
 |
Dr. Christopher Ball, Asset Partner, IQVIA Christopher (MD, MBA) is a biotech asset partner at IQVIA. He helps high-potential biotechs accelerate time to market, reduce risk and maximize peak sales by providing access to IQVIA’s evidence-based insights and tailored holistic solutions. He has previously worked as CEO of a US commercial-stage biotech, a venture capital investor and in strategic marketing at Johnson and Johnson. He started his career as a medical doctor and is trained in internal medicine and clinical epidemiology. Christopher holds a pathology degree from the University of Cambridge, a medical degree from the University of Oxford and an MBA from the Wharton School of Business, University of Pennsylvania. He has written an award-winning book on evidence-based medicine. |
| Organized by | In collaboration with |
 |
 |